Table 2

Eye-level characteristics overall and by vitreous seeding (VS), subretinal seeding (SRS) or both

VS onlySRS onlyBoth VS and SRSOverall
(n=31)(n=15)(n=30)(n=76)
IC group, N (%)
 C14 (45.2)1 (6.7)2 (6.7)17 (22.4)
 D14 (45.2)12 (80.0)23 (76.7)49 (64.5)
 E3 (9.7)2 (13.3)5 (16.7)10 (13.2)
RE group, N (%)
 5A0 (0.0)8 (53.3)0 (0.0)8 (10.5)
 5B31 (100.0)7 (46.7)30 (100.0)68 (89.5)
Previous treatment, N (%)
 No9 (29.0)6 (40.0)14 (46.7)29 (38.2)
 Yes22 (71.0)9 (60.0)16 (53.3)47 (61.8)
Type of previous treatment, N (%)
 1–2 systemic chemo treatments5 (22.7)2 (22.2)2 (12.5)9 (19.1)
 3–6 systemic chemo treatments9 (40.9)4 (44.4)7 (43.8)20 (42.6)
 >6 systemic chemo treatments2 (9.1)0 (0.0)1 (6.3)3 (6.4)
 EBR only0 (0.0)1 (11.1)0 (0.0)1 (2.1)
 EBR + any systemic chemo3 (13.6)1 (11.1)6 (37.5)10 (21.3)
 Local treatment only3 (13.6)1 (11.1)0 (0.0)4 (8.5)
Number of drugs, N (%)
 112 (38.7)7 (46.7)14 (46.7)33 (43.4)
 215 (48.4)6 (40.0)12 (40.0)33 (43.4)
 34 (12.9)2 (13.3)4 (13.3)10 (13.2)
Number of cycles, N (%)
 ≤319 (61.3)12 (80.0)20 (66.7)51 (67.1)
 >312 (38.7)3 (20.0)10 (33.3)25 (32.9)
  • Chemo, chemotherapy; EBR, external beam irradiation; IC, international classification; RE, Reese-Ellsworth; SRS, sub-retinal seeds; VS, vitreous seeds.